Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Canrenone→

Canrenone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
976-71-6
Molecular formula
C22H28O3
Molecular weight
340.5 g/mol
Drug class
Active spironolactone metabolitesteroidal mineralocorticoid-receptor antagonist
Mechanism of action
Competitively antagonises aldosterone at mineralocorticoid receptors in the distal nephron, reducing sodium and water reabsorption and decreasing potassium and hydrogen-ion excretion.
Indications / reported uses
  • Used as a potassium-sparing diuretic and anti-aldosterone agent in selected settings of oedema, hyperaldosteronism and cardiovascular disease; specific authorised indications and dosage forms vary by country

Sources: NLM MeSH — Canrenone · PubChem — Canrenone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Canrenone Environmental Risk Assessment (ERA) (the Canrenone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.